Geode Capital Management LLC Trims Stock Position in Edwards Lifesciences Corporation $EW

Geode Capital Management LLC lessened its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 0.4% during the 4th quarter, Holdings Channel reports. The institutional investor owned 12,784,902 shares of the medical research company’s stock after selling 52,243 shares during the quarter. Geode Capital Management LLC’s holdings in Edwards Lifesciences were worth $1,084,852,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in EW. JPL Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at approximately $25,000. Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Edwards Lifesciences during the 4th quarter valued at approximately $28,000. Hantz Financial Services Inc. raised its position in shares of Edwards Lifesciences by 76.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after buying an additional 164 shares during the period. Dorato Capital Management purchased a new stake in shares of Edwards Lifesciences during the 4th quarter valued at approximately $29,000. Finally, Rakuten Securities Inc. raised its position in shares of Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after buying an additional 302 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Up 0.5%

Edwards Lifesciences stock opened at $86.41 on Friday. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $88.28. The stock’s fifty day simple moving average is $81.73 and its 200-day simple moving average is $83.01. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $49.76 billion, a P/E ratio of 45.96, a P/E/G ratio of 2.15 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The business had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. During the same quarter in the prior year, the company earned $0.64 earnings per share. The company’s revenue was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, equities analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

EW has been the topic of several analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Monday, April 20th. Canaccord Genuity Group set a $85.00 price target on shares of Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday, April 24th. Robert W. Baird boosted their target price on Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research report on Friday, April 24th. Truist Financial set a $90.00 target price on Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday, April 24th. Finally, Wells Fargo & Company boosted their target price on Edwards Lifesciences from $96.00 to $100.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $95.65.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $83.01, for a total transaction of $84,587.19. Following the completion of the transaction, the vice president owned 33,934 shares in the company, valued at approximately $2,816,861.34. The trade was a 2.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the transaction, the chief financial officer owned 39,699 shares of the company’s stock, valued at approximately $3,177,507.96. The trade was a 24.67% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 106,397 shares of company stock worth $8,848,664. Corporate insiders own 0.31% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.